Reinnervate Launcews Alvetex®: Enabling Routine 3D Cell Culture

Reinnervate, an innovative life sciences company driving the adoption of routine 3D cell culture, is very pleased to announce today the first commercial launch of alvetex®, its breakthrough 3D cell culture technology.

Alvetex® is a unique material that provides a robust and inert scaffold for cells to grow and form complex 3D cell structures in the laboratory, mimicking the normal growth and formation of tissues in the body.

Reinnervate has extensively tested and validated alvetex® with a large number of cell types, including liver, skin, cancer and stem cells, all of which have important applications in basic research into cell development, disease modelling and drug safety screening.

The first alvetex® format to be launched is a 12 well plate (see picture) designed as an off-the-shelf, sterile-packed and ready-to-use product and will be available via international life science product distributors. Alvetex®, seen as a white membrane at the bottom of each well, has a highly porous architecture that is specifically tailored for 3D cell culture and is compatible with a large number of well-known cellular and molecular assay techniques.

The Company plans over the next 12-18 months to introduce alvetex® products in a range of standard multi-well plates including those suitable for high-throughput drug screening, and unique well inserts that enable long-term 3D cell culture over several weeks. Alvetex® is designed and developed with the needs of cell biologists in mind and will allow researchers in academia and the pharmaceutical and related industries to construct different 3D cell culture models to meet their specific research needs.

Ashley Cooper, CEO of reinnervate, said: “There is a real need for a technology that can allow the routine generation of genuine 3D cell cultures in the laboratory. This need is being reflected in the considerable level of interest being expressed by international life sciences products companies to distribute alvetex® products. The first commercial launch of this innovate product is a great achievement for all involved in its development at reinnervate and many congratulations are deserved.”

Professor Stefan Przyborski, reinnervate’s Chief Scientific Officer and founder, said: “We are extremely proud to launch alvetex® following the intense development efforts of our innovative and highly dedicated team. We believe we have created a truly game-changing technology for which there is huge demand, and that will enable rapid and important advances in our understanding of cell behaviour and ultimately lead to novel therapeutic approaches.”